Figure 1.

High-risk gene signatures are differentially prognostic for PFS in patients treated with bendamustine vs CHOP/CVP. Summary scores were calculated for 5 published gene signatures. High risk for (A) the PRIMA 23-gene signature was defined as patients in the top 25th percentile or (B) the top 75th percentile for the T-effector signature. Patients were split by high-risk status and chemotherapy group, and PFS was plotted as a Kaplan-Meier curve. HR and P value for an interaction term are included. (C) High-risk definitions for gene signatures were evaluated at 3 different quartile cutoffs (25th, 50th, and 75th percentiles). PFS HRs and 95% CIs in the CHOP/CVP cohort (blue) or the bendamustine cohort (red) are plotted. CI, confidence interval; HR, hazard ratio.